BACKGROUND: Surgical resection is the only therapeutic option with curative effect on malignant liver tumours, but in over 70% of cases, this is not a feasible option. A prospective study was performed to assess the short- and long-term effects of intraoperative radiofrequency ablation on unresectable liver metastases. PATIENTS: Between 1997 and 2001, 57 patients (mean age 61.9 years; range 31-83 years) with 297 unresectable liver metastases (colorectal adenocarcinoma, n=38; carcinoid tumour, n=4; malignant melanoma, n=3; other metastases, n=12) underwent intraoperative radiofrequency ablation. RESULTS: No mortality was observed in patients managed solely with radiofrequency ablation. Eight postoperative complications occurred in eight patients (14%). Three occurred when radiofrequency ablation was combined with resection. Of the 33 patients completely ablated, 30 patients are still alive and 21 are disease-free after a median follow-up of 18.1 months (range 2-43). Ten patients underwent more than one intraoperative radiofrequency ablation episode. Overall survival was 72.5% at 1 year and 52.5% at 3 years. Complete ablation and the number of lesions were significant independent prognostic factors for survival, with p<0.001 and p<0.0001, respectively. CONCLUSION: Radiofrequency ablation is a safe and effective option for patients with inoperable liver metastases without extra hepatic disease. Prospective controlled trials comparing the results of different treatments are required to assess which patients will benefit best from this emerging new treatment.
BACKGROUND: Surgical resection is the only therapeutic option with curative effect on malignant liver tumours, but in over 70% of cases, this is not a feasible option. A prospective study was performed to assess the short- and long-term effects of intraoperative radiofrequency ablation on unresectable liver metastases. PATIENTS: Between 1997 and 2001, 57 patients (mean age 61.9 years; range 31-83 years) with 297 unresectable liver metastases (colorectal adenocarcinoma, n=38; carcinoid tumour, n=4; malignant melanoma, n=3; other metastases, n=12) underwent intraoperative radiofrequency ablation. RESULTS: No mortality was observed in patients managed solely with radiofrequency ablation. Eight postoperative complications occurred in eight patients (14%). Three occurred when radiofrequency ablation was combined with resection. Of the 33 patients completely ablated, 30 patients are still alive and 21 are disease-free after a median follow-up of 18.1 months (range 2-43). Ten patients underwent more than one intraoperative radiofrequency ablation episode. Overall survival was 72.5% at 1 year and 52.5% at 3 years. Complete ablation and the number of lesions were significant independent prognostic factors for survival, with p<0.001 and p<0.0001, respectively. CONCLUSION: Radiofrequency ablation is a safe and effective option for patients with inoperable liver metastases without extra hepatic disease. Prospective controlled trials comparing the results of different treatments are required to assess which patients will benefit best from this emerging new treatment.
Authors: Osman Civil; Metin Kement; Nuri Okkabaz; Mustafa Haksal; Cem Gezen; Mustafa Oncel Journal: Indian J Surg Date: 2015-06-05 Impact factor: 0.656
Authors: Madhava Pai; Long R Jiao; Shirin Khorsandi; Ruben Canelo; Duncan R C Spalding; Nagy A Habib Journal: HPB (Oxford) Date: 2008 Impact factor: 3.647
Authors: Bram Fioole; Maarten C Jansen; Frederieke H van Duijnhoven; Richard van Hillegersberg; Thomas M van Gulik; Inne Hm Borel Rinkes Journal: World J Surg Oncol Date: 2006-07-17 Impact factor: 2.754
Authors: Pradeep S Virdee; Joanna Moschandreas; Val Gebski; Sharon B Love; E Anne Francis; Harpreet S Wasan; Guy van Hazel; Peter Gibbs; Ricky A Sharma Journal: JMIR Res Protoc Date: 2017-03-28
Authors: Peter Gibbs; Val Gebski; Mark Van Buskirk; Kenneth Thurston; David N Cade; Guy A Van Hazel Journal: BMC Cancer Date: 2014-12-01 Impact factor: 4.430